Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News NeuroDerm Ltd NDRM

Healthcare Biotechnology
"NeuroDerm Ltd is a clinical-stage pharmaceutical company developing next-generation treatments for central nervous system diseases, including Parkinson's disease as well as other CNS diseases."

Recent & Breaking News (NDAQ:NDRM)

NeuroDerm Provides Updates on ND0612 Long-Term Safety Trial and Submission of Marketing Applications

GlobeNewswire September 29, 2016

NeuroDerm’s ND0612 Mini-Pump Delivery System Successfully Used by Parkinson’s Disease Patients in Home Setting

GlobeNewswire September 22, 2016

NeuroDerm to Present ND0612 Data at 4th World Parkinson Congress Demonstrating Ease of Use of Mini-Pump Delivery System

GlobeNewswire September 19, 2016

NeuroDerm Announces Second Quarter 2016 Financial Results and Provides Corporate Update

GlobeNewswire August 25, 2016

NeuroDerm Initiates Patient Enrollment in a Phase III Trial of ND0612L for the Treatment of Parkinson’s Disease

GlobeNewswire August 25, 2016

NeuroDerm to Host Second Quarter 2016 Financial Results Conference Call on August 25, 2016

GlobeNewswire August 11, 2016

NeuroDerm Announces Issuance of a New U.S. Patent for Aqueous Apomorphine Covering Concentrated Subcutaneously Delivered Pharmaceutical Compositions

GlobeNewswire July 27, 2016

NeuroDerm Announces Start of Bioequivalence Trial in Healthy Volunteers of ND0701, a New Continuous Subcutaneously Delivered Apomorphine Product Candidate for the Treatment of Advanced Parkinson’s Disease

GlobeNewswire July 26, 2016

NeuroDerm Announces Additions to Management Team

GlobeNewswire July 6, 2016

NeuroDerm to Present at the Cantor Fitzgerald Healthcare Conference on July 13

GlobeNewswire July 5, 2016

NeuroDerm Announces Start of U.S. Patient Enrollment in Trial 006, a Phase II Trial of ND0612H for Advanced Parkinson’s Disease

GlobeNewswire June 30, 2016

NeuroDerm Announces ND0612H Achieves Comparable Pharmacokinetics to DUODOPA® in Head-To-Head Pilot PK Comparison Trial

GlobeNewswire June 28, 2016

NeuroDerm Added to Russell Global Index

GlobeNewswire June 24, 2016

NeuroDerm Presents Three Posters at the 20th International Congress of Parkinson’s Disease and Movement Disorders

GlobeNewswire June 23, 2016

NeuroDerm to Present Design of the First Clinical Efficacy Study of ND0612H and Other Clinical Data at the 20th International Congress of Parkinson’s Disease and Movement Disorders

GlobeNewswire June 16, 2016

NeuroDerm CEO to Present at Jefferies 2016 Healthcare Conference on June 7

GlobeNewswire May 31, 2016

NeuroDerm Announces First Quarter 2016 Financial Results

GlobeNewswire May 26, 2016

NeuroDerm to Host First Quarter 2016 Financial Results Conference Call on May 26, 2016

GlobeNewswire May 17, 2016

NeuroDerm Announces Patient Enrollment in Long-Term Safety Trial of ND0612 for Parkinson’s Disease

GlobeNewswire May 9, 2016

NeuroDerm Announces 2016 Annual General Meeting of Shareholders

GlobeNewswire May 5, 2016